EGFR-mutant lung cancer: Cracking the drug resistance code

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade, particularly for patients whose tumours harbour mutations in the epidermal growth factor receptor (EGFR). Among these, osimertinib has emerged as a frontline standard of care, delivering meaningful improvements in progression-free survival and overall outcomes.

Yet, despite these advances, one reality continues to define the clinical trajectory for most patients: treatment resistance is inevitable. Recent research is taking aim at this challenge by engineering a panel of advanced models that replicate clinically observed resistance mechanisms and make them available to researchers worldwide.

The complexity of resistance

In the Phase III FLAURA trial, osimertinib demonstrated response rates of approximately 80%, however, the median progression-free survival was just 18.9 months.[i] Under the selective pressure of targeted therapy, tumours evolve rapidly, acquiring new mutations or activating bypass signalling networks such as KRAS, BRAF, or PI3K pathways that ultimately undermine the durability of these therapies.[ii]

This persistent challenge highlights a fundamental gap in oncology: our ability to predict, understand, and ultimately overcome resistance lags behind our capacity to develop targeted drugs.

Traditional approaches to studying resistance often rely on the generation of resistance cell cultures through prolonged drug exposure in vitro. These methods are time- and labour-intensive and lack clearly defined drug-resistant mechanisms, which frequently yield results that are difficult to interpret. Efforts to use fresh patient samples are hampered by limited availability. The continued requirement for selection pressure further complicates downstream applications, including secondary drug screening and functional studies. Moreover, these samples typically represent a single snapshot in time, limiting our ability to systematically study how resistance emerges and evolves.

To move beyond these limitations, the field needs scalable, reproducible systems that allow researchers to model resistance in a controlled and systematic way.

Engineering resistance to understand it

To address this challenge, the researchers at ATCC and the Broad Institute of MIT and Harvard collaborated to develop drug-resistant isogenic cell lines that replicate clinically observed resistance mechanisms to targeted therapies.

Using CRISPR gene editing techniques, the team created a panel of 13 isogenic NSCLC cell lines, each built from well-characterised, drug-sensitive parental cell lines and engineered to harbour a specific resistance mechanism to osimertinib observed in patients.

The six resistance mechanisms were selected to reflect the landscape of clinically observed resistance, spanning direct EGFR mutations, RAS/MAPK pathway activation, and oncogenic fusions that are notoriously difficult to study with conventional patient-derived samples: PIK3CA E545K mutation, KRAS G12D mutation, BRAF V600E mutation, EGFR C797S mutation, CCDC6-RET fusion, and TPM3 - NTRK1 fusion.

By design, these models differ from their parental counterparts by a single genetic alteration, enabling side-by-side comparisons between drug-sensitive and drug-resistant cells.

From models to mechanisms

Instead of relying on rare patient samples, scalability is possible and researchers can now systematically engineer and study multiple resistance pathways in parallel and with greater speed – accelerating the pace of discovery and permitting scientists to identify common patterns and vulnerabilities that might otherwise remain hidden.

Comparing how different resistance mechanisms respond to combination therapies can reveal opportunities to overcome resistance before it emerges clinically. Similarly, these models can help identify biomarkers that predict which patients are most likely to develop specific resistance pathways.

Ultimately, this work helps to shift the paradigm from reactive to proactive. Rather than waiting for resistance to arise in patients, researchers can anticipate and begin to study it in the laboratory.

Building a map of cancer vulnerabilities

A key component of this effort is a commitment to making these models broadly accessible. The engineered models and associated genomic datasets discussed above, for example, will be made available through ATCC and integrated into a Cancer Dependency Map (DepMap), allowing researchers to contribute to the ongoing development of a Response and Resistance Map (ResMap): an emerging framework that seeks to systematically characterise how cancers respond to therapy and how resistance evolves.

Such an integrated approach combines functional genomics, computational biology, and high-quality biological models to create a comprehensive view of cancer vulnerabilities. Researchers can start to ask more sophisticated questions: Which pathways become essential when resistance develops? Are there shared dependencies across different resistance mechanisms? Can these dependencies be targeted therapeutically?

Enabling global collaboration

An open-access model is also critical for accelerating progress. Drug resistance is a complex, multifaceted problem that cannot be solved in isolation. By providing standardised, high-quality models, and datasets to the global research community, scientists across academia, industry, and government can work from a shared foundation.

It also underscores the importance of connecting physical biological materials with their digital counterparts. Reliable data is only as strong as the materials from which it is derived. Ensuring traceability between cell lines and their associated genomic data is essential for reproducibility. This is increasingly important as advanced computational approaches, including artificial intelligence (AI), play an increasingly central role in drug discovery.

Looking ahead

The challenge of drug resistance is not unique to EGFR-mutant lung cancer. It is a defining feature of oncology more broadly. However, by developing scalable, reproducible systems to study resistance, we can begin to shift the trajectory.

For patients, the ultimate goal is clear: treatments that not only work initially, but continue to work over time. Achieving that goal will require not just better drugs, but better models, better data, and a more integrated approach to understanding cancer biology.

References

[i] Soria JG, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. New England Journal of Medicine. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137, https://www.nejm.org/doi/full/10.1056/NEJMoa1713137.

[ii] Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. British Journal of Cancer. 2019;121(9):725–737. doi:10.1038/s41416-019-0573-8, Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer | British Journal of Cancer.

About the author

Fang Tian, PhD, is director of biological content at ATCC. She brings more than 20 years of experience in cell biology, molecular biology, and genome editing to her role. Dr Tian oversees human and animal cell lines, hybridomas, and product development within ATCC’s Cell Biology General Collection, supporting the advancement of high-quality, authenticated biological resources. Dr Tian has a research background in cancer biology and functional genomics, with particular experience in CRISPR-based genome editing to study disease mechanisms and identify therapeutic targets. She previously conducted research at Massachusetts General Hospital and Harvard Medical School, and completed postdoctoral work at the Hillman Cancer Institute at the University of Pittsburgh Medical Center, where her work focused on cancer research and translational applications.